Collegium Pharmaceutical, Inc. (COLL) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1241315,
    "name": "Collegium Pharmaceutical, Inc.",
    "stock_name": "Collegium Pharmaceutical, Inc.",
    "full_name": "Collegium Pharmaceutical, Inc.",
    "name_url": "stocks-analysis/collegium-pharmaceutical-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "47.43",
    "chg": -0.08,
    "chgp": "-0.17%",
    "dir": -1,
    "prev_price": "47.51",
    "mcapval": "1,221.63",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US19459J1043",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "540.13 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/collegium-pharmaceutical-inc-1241315-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Collegium Pharmaceutical Hits New 52-Week High at $43.06",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/collegium-pharmaceutical-hits-new-52-week-high-at-4306-3686432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CollegiumPharma_priceRelatedfactors_3686432.png",
        "date": "2025-11-10 17:09:58",
        "description": "Collegium Pharmaceutical, Inc. achieved a new 52-week high, reflecting strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 1,222 million, the company shows effective management through a return on equity of 23.11%, despite a higher reliance on debt financing and no dividend offerings."
      },
      {
        "title": "Collegium Pharmaceutical, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/collegium-pharmaceuticals-valuation-grade-changes-from-expensive-to-fair-amid-stock-price-increase-3686318",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CollegiumPharma_valuationdot_3686318.png",
        "date": "2025-11-10 16:12:28",
        "description": "Collegium Pharmaceutical, Inc. has adjusted its valuation, showcasing a favorable P/E ratio of 15 and strong profitability metrics, including a ROCE of 16.93% and ROE of 28.03%. The company has outperformed the S&P 500 in stock returns over both year-to-date and annual periods, highlighting its competitive market position."
      },
      {
        "title": "Collegium Pharmaceutical Hits Day High with 13.7% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/collegium-pharmaceutical-hits-day-high-with-137-surge-in-stock-price-3680235",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CollegiumPharma_priceRelatedfactors_3680235.png",
        "date": "2025-11-07 16:35:12",
        "description": "Collegium Pharmaceutical, Inc. has seen notable stock activity, with a significant increase today and strong weekly and monthly gains. Despite its annual performance exceeding that of the S&P 500, the company faces challenges, including a low EBIT to Interest ratio and a decline in pre-tax profit in its latest quarterly results."
      },
      {
        "title": "Collegium Pharmaceutical Hits New 52-Week High at $41.81",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/collegium-pharmaceutical-hits-new-52-week-high-at-4181-3680158",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CollegiumPharma_priceRelatedfactors_3680158.png",
        "date": "2025-11-07 16:02:50",
        "description": "Collegium Pharmaceutical, Inc. achieved a new 52-week high of USD 41.81 on November 6, 2025, reflecting strong performance over the past year. The company, with a market cap of USD 1,222 million, has shown a one-year growth of 22.07%, outperforming the S&P 500. Key metrics indicate solid financial health despite a high debt-to-equity ratio."
      },
      {
        "title": "Is Collegium Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-collegium-pharmaceutical-inc-technically-bullish-or-bearish-3673622",
        "imagepath": "",
        "date": "2025-11-05 11:21:09",
        "description": "As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands indicate bullish conditions. However, the MACD shows a mildly bearish stance on the weekly timeframe, while the monthly is bullish. The Dow Theory presents a mildly bullish view on the weekly but is mildly bearish on the monthly.\n\nIn terms of performance, Collegium has outperformed the S&P 500 in the past week (2.71% vs. 0.71%), the past month (3.32% vs. 1.92%), and year-to-date (24.82% vs. 16.30%), but lags behind over the past year (6.87% vs. 19.89%) and the past five years (91.74% vs. 109.18%). Overall, the current technical stance is bullish, with moderate strength indicated by mixed signals across different timeframes...."
      },
      {
        "title": "Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/collegium-pharmaceuticals-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-price-increase-3671412",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CollegiumPharma_technicaldot_3671412.png",
        "date": "2025-11-04 16:07:33",
        "description": "Collegium Pharmaceutical, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $36.10. The company has experienced significant volatility over the past year, with a high of $39.95 and a low of $23.23, while showing mixed technical indicators and notable performance relative to the S&P 500."
      },
      {
        "title": "Is Collegium Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-collegium-pharmaceutical-inc-technically-bullish-or-bearish-3670803",
        "imagepath": "",
        "date": "2025-11-04 11:32:31",
        "description": "As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by daily moving averages indicating bullish momentum, and both weekly and monthly Bollinger Bands also signaling bullish conditions. However, the MACD shows a mildly bearish signal on the weekly timeframe, which suggests some caution. The stock has outperformed the S&P 500 over the past week and month, with returns of 3.69% and 4.31% compared to the benchmark's 0.71% and 1.92%, respectively. Overall, the strength of the bullish trend is tempered by mixed signals from the MACD and KST indicators...."
      },
      {
        "title": "Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/collegium-pharmaceuticals-valuation-grade-changes-from-fair-to-expensive-amidst-market-performance-3667170",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CollegiumPharma_valuationdot_3667170.png",
        "date": "2025-11-03 16:07:30",
        "description": "Collegium Pharmaceutical, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 15 and a price-to-book value of 4.25. The company exhibits strong operational efficiency with a return on equity of 28.03% and a year-to-date stock performance of 25.65%, surpassing the S&P 500."
      },
      {
        "title": "Is Collegium Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-collegium-pharmaceutical-inc-technically-bullish-or-bearish-3666401",
        "imagepath": "",
        "date": "2025-11-03 11:31:58",
        "description": "As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by daily moving averages indicating strength. Monthly Bollinger Bands and OBV are also bullish, while the MACD shows a bullish signal on the monthly timeframe, despite being mildly bearish on the weekly. The Dow Theory indicates a mildly bullish trend on the monthly timeframe. \n\nIn terms of performance, the stock has outperformed the S&P 500 over the year-to-date with a return of 25.65% compared to the S&P 500's 16.30%, although it has lagged over the 1-year and 5-year periods...."
      }
    ],
    "total": 20,
    "sid": "1241315",
    "stock_news_url": "https://www.marketsmojo.com/news/collegium-pharmaceutical-inc-1241315"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Collegium Pharmaceutical Hits New 52-Week High at $43.06

2025-11-10 17:09:58

Collegium Pharmaceutical, Inc. achieved a new 52-week high, reflecting strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 1,222 million, the company shows effective management through a return on equity of 23.11%, despite a higher reliance on debt financing and no dividend offerings.

Collegium Pharmaceutical, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics

2025-11-10 16:12:28

Collegium Pharmaceutical, Inc. has adjusted its valuation, showcasing a favorable P/E ratio of 15 and strong profitability metrics, including a ROCE of 16.93% and ROE of 28.03%. The company has outperformed the S&P 500 in stock returns over both year-to-date and annual periods, highlighting its competitive market position.

Collegium Pharmaceutical Hits Day High with 13.7% Surge in Stock Price

2025-11-07 16:35:12

Collegium Pharmaceutical, Inc. has seen notable stock activity, with a significant increase today and strong weekly and monthly gains. Despite its annual performance exceeding that of the S&P 500, the company faces challenges, including a low EBIT to Interest ratio and a decline in pre-tax profit in its latest quarterly results.

Collegium Pharmaceutical Hits New 52-Week High at $41.81

2025-11-07 16:02:50

Collegium Pharmaceutical, Inc. achieved a new 52-week high of USD 41.81 on November 6, 2025, reflecting strong performance over the past year. The company, with a market cap of USD 1,222 million, has shown a one-year growth of 22.07%, outperforming the S&P 500. Key metrics indicate solid financial health despite a high debt-to-equity ratio.

Is Collegium Pharmaceutical, Inc. technically bullish or bearish?

2025-11-05 11:21:09

As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The daily moving averages are bullish, and both the weekly and monthly Bollinger Bands indicate bullish conditions. However, the MACD shows a mildly bearish stance on the weekly timeframe, while the monthly is bullish. The Dow Theory presents a mildly bullish view on the weekly but is mildly bearish on the monthly. In terms of performance, Collegium has outperformed the S&P 500 in the past week (2.71% vs. 0.71%), the past month (3.32% vs. 1.92%), and year-to-date (24.82% vs. 16.30%), but lags behind over the past year (6.87% vs. 19.89%) and the past five years (91.74% vs. 109.18%). Overall, the current technical stance is bullish, with moderate strength indicated by mixed signals across different timeframes....

Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-11-04 16:07:33

Collegium Pharmaceutical, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $36.10. The company has experienced significant volatility over the past year, with a high of $39.95 and a low of $23.23, while showing mixed technical indicators and notable performance relative to the S&P 500.

Is Collegium Pharmaceutical, Inc. technically bullish or bearish?

2025-11-04 11:32:31

As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by daily moving averages indicating bullish momentum, and both weekly and monthly Bollinger Bands also signaling bullish conditions. However, the MACD shows a mildly bearish signal on the weekly timeframe, which suggests some caution. The stock has outperformed the S&P 500 over the past week and month, with returns of 3.69% and 4.31% compared to the benchmark's 0.71% and 1.92%, respectively. Overall, the strength of the bullish trend is tempered by mixed signals from the MACD and KST indicators....

Collegium Pharmaceutical Experiences Revision in Stock Evaluation Amid Strong Market Performance

2025-11-03 16:07:30

Collegium Pharmaceutical, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 15 and a price-to-book value of 4.25. The company exhibits strong operational efficiency with a return on equity of 28.03% and a year-to-date stock performance of 25.65%, surpassing the S&P 500.

Is Collegium Pharmaceutical, Inc. technically bullish or bearish?

2025-11-03 11:31:58

As of 31 October 2025, the technical trend for Collegium Pharmaceutical, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by daily moving averages indicating strength. Monthly Bollinger Bands and OBV are also bullish, while the MACD shows a bullish signal on the monthly timeframe, despite being mildly bearish on the weekly. The Dow Theory indicates a mildly bullish trend on the monthly timeframe. In terms of performance, the stock has outperformed the S&P 500 over the year-to-date with a return of 25.65% compared to the S&P 500's 16.30%, although it has lagged over the 1-year and 5-year periods....

View All News